About TransCode Therapeutics
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor.
The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M.
D. Anderson Cancer Center.
The company was incorporated in 2016 and is based in Boston, Massachusetts.